Search Results - A. Truppel-Hartmann

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY by P Rodríguez-Otero, J San-Miguel, LD Anderson, Jr, S Lonial, A Truppel-Hartmann, J Sanford, E Rowe, TB Campbell, N Munshi

    Published in HemaSphere (2022-04-01)
    Get full text
    Article


  2. 2

    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... by P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

    Published in HemaSphere (2023-05-01)
    Get full text
    Article


Search Tools: